"I look upon my time as part of the Sontag research family with great fondness and I continue to watch with pride the accomplishments of the Foundation and look forward each year to meeting the next cohort of scientists."
About DSA-Funded Research
Dr. Taylor's aim is to bridge the gap between the ability to detect mutations in tumors and the accurate interpretation of their impact on the evolution of disease and then apply that knowledge to personalize the care of individual glioma patients. His current position at Loxo Oncology at Lilly brings together the focus and spirit of a biotech with the scale and resources of large pharma, with the goal of rapidly delivering impactful new medicines for people with cancer. Their approach centers on creating new medicines that unequivocally work early in clinical development and will matter to patients with the intention to curate a balanced pipeline of medicines, either internally or externally discovered, with the potential to treat cancer with dramatic effect.
Vice President, Loxo Oncology at Lilly, Eli Lilly, New York, New York
University of California, San Diego, B.S., Cognitive Science
University of Michigan, M.S., Bioinformatics
Weill Medical College of Cornell University, Ph.D., Physiology, Biophysics, Systems Biology
Memorial Sloan-Kettering Cancer Center, Fellowship, Cancer Genomics